[go: up one dir, main page]

WO1997037029B1 - ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS - Google Patents

ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS

Info

Publication number
WO1997037029B1
WO1997037029B1 PCT/US1997/004198 US9704198W WO9737029B1 WO 1997037029 B1 WO1997037029 B1 WO 1997037029B1 US 9704198 W US9704198 W US 9704198W WO 9737029 B1 WO9737029 B1 WO 9737029B1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antibody according
pdgf
amino acid
acid sequence
Prior art date
Application number
PCT/US1997/004198
Other languages
English (en)
Other versions
WO1997037029A1 (fr
Filing date
Publication date
Priority claimed from US08/621,751 external-priority patent/US5882644A/en
Application filed filed Critical
Priority to AU23298/97A priority Critical patent/AU2329897A/en
Publication of WO1997037029A1 publication Critical patent/WO1997037029A1/fr
Publication of WO1997037029B1 publication Critical patent/WO1997037029B1/fr

Links

Abstract

Cette invention se rapporte à des anticorps monoclonaux, à des anticorps monoclonaux humanisés et à des dérivés fonctionnels de ces anticorps, spécifiques du récepteur du facteur de croissance issu des plaquettes β. Des procédés d'utilisation de cet anticorps, en particulier pour soigner la resténose, sont également présentés.
PCT/US1997/004198 1996-03-22 1997-03-19 ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS WO1997037029A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23298/97A AU2329897A (en) 1996-03-22 1997-03-19 Monoclonal antibodies specific for the platelet derived growth factor beta receptor and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/621,751 1996-03-22
US08/621,751 US5882644A (en) 1996-03-22 1996-03-22 Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof

Publications (2)

Publication Number Publication Date
WO1997037029A1 WO1997037029A1 (fr) 1997-10-09
WO1997037029B1 true WO1997037029B1 (fr) 1997-12-18

Family

ID=24491483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004198 WO1997037029A1 (fr) 1996-03-22 1997-03-19 ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS

Country Status (3)

Country Link
US (1) US5882644A (fr)
AU (1) AU2329897A (fr)
WO (1) WO1997037029A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US20020044933A1 (en) * 1993-02-25 2002-04-18 Hart Charles E. Inhibition of intimal hyperplasia using antibodies to PDGF receptors
US6114110A (en) * 1996-01-16 2000-09-05 University Of Michigan Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
WO1998035697A1 (fr) * 1997-02-14 1998-08-20 Roche Diagnostics Gmbh Procede ameliore permettant de reduire la formation de cellules neointimes apres une angioplastie
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
ITMI20002832A1 (it) * 2000-12-27 2002-06-27 Acetum S R L Salsa balsamica per uso alimentare a base di aceto balsamico di modena
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7172758B2 (en) * 2002-01-29 2007-02-06 Colb A Mark Endothelialization of vascular surfaces
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
MXPA06011952A (es) * 2004-04-16 2007-01-16 Scripps Research Inst Metodo para modulacion de vascularizacion.
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
PT2087002E (pt) * 2006-10-27 2014-11-26 Lpath Inc Composições e métodos para a ligação de esfingosina-1- fosfato
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (fr) * 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Procédé pour le traitement des amyloses
UA99608C2 (en) 2007-04-17 2012-09-10 Имклоун Ллк PDGFRb-SPECIFIC INHIBITORS
WO2008131242A1 (fr) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Fc à chaîne simple, procédés de fabrication et procédés de traitement
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2008150841A1 (fr) 2007-05-30 2008-12-11 Lpath, Inc. Compositions et procédés pour lier de l'acide lysophosphatidique
CN103694351A (zh) 2007-06-05 2014-04-02 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
HRP20140244T1 (hr) * 2008-03-27 2014-04-11 Zymogenetics, Inc. Sastavi i metode za inhibiranje pdgfrbeta i vegf-a
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
JP2012511026A (ja) * 2008-12-05 2012-05-17 エルパス・インコーポレイテッド 抗脂抗体結晶構造を用いた抗体設計
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP2400985A2 (fr) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Thérapie anti-cancer combinée
EP2400981A4 (fr) * 2009-02-26 2013-02-27 Lpath Inc Conception d'anticorps humanisé anti-facteur d'activation plaquettaire à l'aide de modèles d'anticorps anti-lipide
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
EP2401614A1 (fr) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
WO2010099364A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
EP2419446A4 (fr) * 2009-04-17 2013-01-23 Lpath Inc Compositions d'anticorps humanisés et procédés de liaison d'acide lysophosphatidique
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
US8754195B2 (en) 2010-07-02 2014-06-17 Medimmune, Llc Antibody formulations
EP3533803B1 (fr) 2010-08-14 2021-10-27 AbbVie Inc. Anticorps anti-bêta-amyloïde
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
MX360620B (es) 2012-07-25 2018-11-09 Celldex Therapeutics Inc Anticuerpos anti kit y usos de los mismos.
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US10702608B2 (en) 2013-09-08 2020-07-07 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
EP3161000A4 (fr) * 2014-06-28 2018-05-02 Kodiak Sciences Inc. Doubles antagonistes de pdgf/vegf
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
JP2018517660A (ja) 2015-03-20 2018-07-05 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 周皮細胞長鎖非コーディングｒｎａ
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
EP3625254B1 (fr) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Procédé d'humanisation fondé sur une structure tridimensionnelle
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2019195561A2 (fr) 2018-04-06 2019-10-10 BioLegend, Inc. Agents anti-tétraspanine 33 et compositions et procédés pour la fabrication et l'utilisation de ces agents
EP3856343A1 (fr) 2018-09-25 2021-08-04 Biolegend, Inc. Agents anti-tlr9 et compositions et procédés pour les préparer et les utiliser
EP4041312A4 (fr) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
EP4090681A1 (fr) 2020-01-17 2022-11-23 Biolegend, Inc. Agents anti-tlr7 et compositions et procédés de fabrication et d'utilisation de ceux-ci
KR20220140551A (ko) * 2020-02-07 2022-10-18 바이오리온 테크놀러지스 비.브이. 혈소판 유래 성장 인자 수용체(pdgfr) 항체, 이의 컨쥬게이트, 조성물 및 용도
WO2022093640A1 (fr) 2020-10-30 2022-05-05 BioLegend, Inc. Agents anti-nkg2c et compositions et méthodes de production et d'utilisation de ceux-ci
WO2022093641A1 (fr) 2020-10-30 2022-05-05 BioLegend, Inc. Agents anti-nkg2a et compositions et méthodes de production et d'utilisation de ceux-ci
TW202317632A (zh) * 2021-07-02 2023-05-01 大陸商來凱醫藥科技（上海）有限公司 已活化肝臟星狀細胞（ｈｓｃ）之耗竭及其用途
EP4558523A1 (fr) 2022-07-19 2025-05-28 Biolegend, Inc. Anticorps anti-cd157, fragments de liaison à l'antigène de ceux-ci, compositions, procédés de fabrication et d'utilisation de ceux-ci
CN119968395A (zh) 2022-08-18 2025-05-09 百进生物科技公司 抗axl抗体、其抗原结合片段及其制备和使用方法
WO2024243217A1 (fr) 2023-05-25 2024-11-28 BioLegend, Inc. Anticorps liant ceacam6 et fragments de liaison à l'antigène de ceux-ci
WO2025072313A1 (fr) 2023-09-27 2025-04-03 BioLegend, Inc. Anticorps anti-gpc4

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
NZ246242A (en) * 1991-12-02 1996-01-26 Cor Therapeutics Inc Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)
DE69413009T2 (de) * 1993-02-25 1999-03-25 University of Washington, Seattle, Wash. Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors

Similar Documents

Publication Publication Date Title
WO1997037029B1 (fr) ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS
Wheelock et al. Soluble 80‐kd fragment of cell‐CAM 120/80 disrupts cell‐cell adhesion
Soncin et al. Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells
Bayer et al. [4] Biotin-binding proteins: Overview and prospects
WO1998050431A3 (fr) Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
CA2128784C (fr) Complexes latents de haut poids moleculaire de tgf-beta2 et de tgf-beta3
EP0930366A3 (fr) Domaines de liaison de la protéine serrate
TWI318983B (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
UA40621C2 (uk) Моноклональне антитіло, гібридомна клітинна лінія, поліпептид (варіанти), фрагмент днк (варіанти), фармацевтична композиція, спосіб одержання моноклонального антитіла
CA2189657A1 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
IL181578A0 (en) Antibodies which are specifically immunoreactive with hedgehog interacting proteins and a hybridoma producing such antibodies
JPH03204896A (ja) インターフェロンレセプター細胞外断片
CA2471762A1 (fr) Inhibiteurs peptidiques, a permeabilite cellulaire, du processus de transduction du signal jnk
WO2000023565A3 (fr) Nouvelle liaison neuropiline/facteur de croissance et applications de celle-ci
EP1141271B1 (fr) Selection d'anticorps monoclonaux
MX9702422A (es) Anticuerpos recombinantes contra fas y adn para los mismos.
WO1995000552B1 (fr) Ce recepteur ep3 de prostaglandines et adn codant
CA2133873A1 (fr) Inhibiteurs du facteur de necrose tumorale (tnf)
WO1999046386B1 (fr) REACTIONS DE ALK-1 AU TGF-β ET DES SIGNAUX TRAVERSANT SMAD-1 ET SMAD-5
WO1999048908A3 (fr) POLYPEPTIDE IMMUNOREACTIF DU RECEPTEUR TrkA du NGF ET UTILISATIONS
Hamel et al. Structural basis for the preferential association of autologous immunoglobulin subunits: role of the J region of the light chain
CA2180957A1 (fr) Clonage et production par recombinaison d'un ou plusieurs recepteurs du facteur liberateur de la corticotrophine
Rong et al. Clustering the mast cell function-associated antigen (MAFA) induces tyrosyl phosphorylation of the FcεRI-β subunit
Lebovitz et al. The Amino Acid Sequence of the Fc Fragment of Rabbit Immunoglobulin G: I. THE ISOLATION AND AMINO ACID COMPOSITION OF TRYPTIC PEPTIDES